Document text
Principal Investigator: Joseph Scaduto
Organization: CMTX BIOTECH, INC.
Fiscal Year: 2021
Award: $315,000
Funding agency: National Center for Advancing Translational Sciences
PROJECT SUMMARY/ABSTRACT
CMTx Biotech is a drug development company working to rescue and repurpose a proprietary clinical-stage drug
candidate, incyclinide (CMT-3 / COL-3), for the treatment of patients infected with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and suffering from Coronavirus disease 2019 (COVID-19). Since late
December 2019, an outbreak of a novel zoonotic coronavirus (SARS-CoV-2 / COVID-19) with clinical
presentations greatly resembling viral pneumonia has claimed the lives of over 418,000 worldwide, including
over 117,000 in the U.S. alone (as of 6/13/2020). COVID-19 is highly contagious, infecting over 7.4 million
patients globally so far, with an average incubation period of 4 days. Frequently reported COVID-19 symptoms
include fever, cough, myalgia or fatigue, and shortness of breath. Approximately 20-30% of hospitalized COVID-
19 patients have required intensive care for respiratory support. COVID-19 can lead to acute lung injury, ARDS,
multiple organ failure and death. Studies have shown that COVID-19 has a mortality rate of up to 4.2%.
Predictors of fatal outcomes include age, the presence of underlying diseases or secondary infection, as well as
elevated inflammatory indicators in the blood, and mortality may be due to virus-activated “cytokine storm
syndrome” or fulminant myocarditis. There is currently no vaccine for COVID-19, and only Remdesivir (Gilead
Sciences) has shown efficacy in a randomized, double-blind, placebo-controlled clinical trial, along with
Emergency Use Authorization from the FDA. Clinical management of COVID-19 patients includes prompt
implementation of recommended infection prevention and control measures, as well as supportive management
of complications, including mechanical ventilation and advanced organ support. CMTx Biotech is working to
repurpose and commercialize incyclinide as a once-daily, orally-administered treatment for hospitalized COVID-
19 patients. Incyclinide is a clinical-stage, non-antibiotic, chemically-modified tetracycline that belongs to a class
of pleiotropic matrix metalloproteinase (MMP) modulators which inhibit pathologically-excessive collagenolysis
and resolve systemic inflammation. Two recent independent studies performed in silico have suggested that
incyclinide may have significant therapeutic benefit in patients with COVID-19. Importantly, the safety of
incyclinide has already been demonstrated in Investigational New Drug (IND)-enabling studies, and incyclinide
has been evaluated in a number of human clinical trials for the treatment of diseases as disparate as AIDS-
related Kaposi's sarcoma, recurrent high-grade gliomas, refractory metastatic cancer, acne, rosacea and
periodontitis. Published pre-clinical efficacy studies have shown that systemic administration of incyclinide
prevents the development of ARDS and septic shock, and improves survival in several chronic insidious onset
animal models of ARDS across several species, including mice, rats, pigs, and sheep. Our long-term goal is to
obtain Emergency Use Authorization (EUA) and regulatory approval from the FDA to market incyclinide for the
safe and effective treatment of COVID-19 patients, as well as to establish a partnership with a pharmaceutical
company in the form of a license or acquisition. We strongly anticipate that incyclinide will inhibit COVID-19
disease progression, mitigate acute lung injury and respiratory distress, reduce the need for intensive care and
intubation, and improve clinical outcomes for COVID-19 patients, including overall survival. Our specific aims
are to design a Phase II clinical study to evaluate the safety and efficacy of incyclinide for the treatment of
hospitalized COVID-19 patients, develop a pre-IND briefing document inclusive of a clinical study synopsis, and
engage the FDA in a pre-IND meeting. Moreover, we intend to prepare key clinical study documents, including
a full clinical study protocol, investigator brochure and informed consent form, along with detailed plans for
statistical analysis, recruitment and retention, and data management, in support of an Investigational New Drug
(IND) submission to the FDA. Successful completion of this clinical trial planning grant will allow us to pursue a
Phase II human clinical study to evaluate a once-daily, orally-administered formulation of incyclinide for the
treatment of hospitalized COVID-19 patients.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><AIDS with Kaposi's sarcoma><AIDS-Related Kaposi's Sarcoma><ARDS><Aching muscles><Acne Rosacea><Acute Lung Injury><Acute Pulmonary Injury><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Age><Animal Model><Animal Models and Related Studies><Area><Autoimmune Deficiency Syndrome-Related Kaposi Sarcoma><Biotech><Biotechnology><Blood><Blood Reticuloendothelial System><Booklets><Brochures><CDC><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 patient><COVID-19 positive patient><COVID-19 therapy><COVID-19 treatment><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 patient><COVID19 positive patient><COVID19 therapy><COVID19 treatment><COVID19 vaccine><COVID19 virus><CV-19><CV19><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cessation of life><Chemicals><Chronic><Chronic Periodontitis><Clinical><Clinical Management><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><CoV-2><CoV2><Common Rat Strains><Computer Analysis><Consent Documents><Consent Forms><Controlled Clinical Trials><Coughing><Da Nang Lung><Death><Development><Disease><Disease Outbreaks><Disease Progression><Disorder><Disseminated Malignant Neoplasm><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Drugs><Epidemic Kaposi's Sarcoma><FDA EUA><FDA Emergency Use Authorization><Family suidae><Fatal Outcome><Fatigue><Fever><Financial Support><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Formulation><GS-5734><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Glioma><Goals><Grant><Human><Infection Control><Infection prevention><Inflammatory><Inflammatory Response><Informed Consent Documents><Informed Consent Forms><Intensive Care><Intubation><Investigational Drugs><Investigational New Drugs><Investigators><Kaposi's Sarcoma Epidemic Type><Knowledge><Lack of Energy><Lead><Licensing><Lung damage><MMPs><MOF syndrome><Matrix Metalloproteinases><Measures><Mechanical ventilation><Medical><Medication><Metastatic Cancer><Metastatic Malignant Neoplasm><Mice><Mice Mammals><Modern Man><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Murine><Mus><Muscle discomfort><Muscle pain><Muscle pain/fibrositis><Muscle sorenesss><Myalgia><Myalgic><Myocarditis><Myodynia><Myoneuralgia><Myosalgia><Neuroglial Neoplasm><Neuroglial Tumor><Oral><Organ><Outbreaks><Outcome><Ovine><Ovis><Pamphlets><Pathologic><Patients><Pb element><Periodontitis><Periostat><Pharmaceutic Preparations><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Phase><Pigs><Placebos><Position><Positioning Attribute><Prevent infection><Protocol><Protocols documentation><Public Health><Publications><Publishing><Pyrexia><Randomized><Rat><Rats Mammals><Rattus><Recurrence><Recurrent><Refractory><Reporting><Research Peer Review><Research Personnel><Researchers><Respiratory Care Units><Respiratory distress><Rosacea><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Science><Scientific Publication><Septic Shock><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Sheep><Shock Lung><Shortness of Breath><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Stiff lung><Suidae><Swine><Symptoms><Syndrome><Tetracyclines><Therapeutic><Therapeutic Intervention><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><Veklury><Viral Pneumonia><Virus><Wuhan coronavirus><ages><cardiac inflammation><computational analyses><computational analysis><computer analyses><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><cytokine release syndrome><cytokine storm><data management><depository><design><designing><developmental><drug candidate><drug development><drug repurposing><drug/agent><effective therapy><effective treatment><efficacy study><emergency use authorization><febrile><febris><financial assistance><glial-derived tumor><hCoV19><heavy metal Pb><heavy metal lead><improved><in silico><intervention therapy><lung injury><mechanical respiratory assist><mechanically ventilated><meetings><model of animal><model organism><mortality><multiorgan failure><multiple organ system failure><nCoV2><neuroglia neoplasm><neuroglia tumor><novel><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><porcine><pre-clinical efficacy><preclinical efficacy><prevent><preventing><randomisation><randomization><randomly assigned><recruit><remdesivir><repository><repurposing agent><repurposing medication><respiratory intensive care><secondary infection><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><sham therapy><statistical analysis><suid><systemic inflammation><systemic inflammatory response><therapeutically effective><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><trial regimen><trial treatment><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><wet lung><zoonotic CoV><zoonotic coronavirus>